SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?


To: richardred who wrote (3546)3/20/2014 12:24:28 AM
From: richardred  Respond to of 7080
 
Valeant CEO Seeks Acquisitions in High-Growth Health Care
By Hugo Miller and Caroline Chen - Mar 19, 2014
Valeant Pharmaceuticals International (VRX) Inc., Canada’s largest drugmaker, said it is seeking acquisitions in opthalmology, dermatology and dentistry.

These areas “are growing faster than the overall growth rate of health care,” Chief Executive Officer Mike Pearson said in an interview on Bloomberg Television today.

Pearson, who took the helm of Valeant in 2008, has spent at least $19 billion buying more than 35 companies as he works toward his goal of making Valeant one of the world’s top five drugmakers by the end of 2016. The $8.7 billion purchase of eyecare company Bausch & Lomb Inc. last year, his biggest to date, added contact lens brand Optima to Valeant’s roster that include the Fraxel laser treatment for skin care and Zovirax for cold sores.

Valeant’s shares have jumped almost tenfold to more than $140 in New York when he took over six years ago as investors have warmed to his acquisition-fueled pledge. That has lifted the market value of the Laval, Quebec-based company which trades in Toronto and New York to about $47 billion, making it the fifth-largest company in Canada as of yesterday.

Valeant remains much smaller than the companies Pearson aims to replicate. Sanofi, the current fifth-largest drugmaker in the world, has a market value of about $134 billion.

bloomberg.com